Solid Biosciences Inc. Cash Flow Statement
SLDB|5 years of annual SEC 10-K data (FY2018-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Solid Biosciences Inc. used $57M in operating cash flow and negative free cash flow of $57M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Net Income | -$88.3M | -$117.2M | -$74.8M | -$52.1M | -$21.5M |
| Depreciation & Amortization | $3.9M | $2.8M | $1.6M | $448.0K | $56.0K |
| Operating Cash Flow | -$56.6M | -$92.7M | -$70.2M | -$43.2M | -$20.1M |
| Capital Expenditures | $899.0K | $4.4M | $7.8M | $2.3M | $392.0K |
| Free Cash Flow | -$57.5M | -$97.1M | -$78.0M | -$45.5M | -$20.5M |
| FCF Margin | -422.2% | - | - | - | - |